2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies

doi:10.1016/j.atherosclerosis.2019.08.014

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

Atherosclerosis. 2019 Nov:290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. Epub 2019 Aug 31.

Authors

Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies

Collaborators

François Mach¹, Colin Baigent², Alberico L Catapano³, Konstantinos C Koskinas⁴, Manuela Casula⁵, Lina Badimon⁶, M John Chapman⁷, Guy G De Backer⁸, Victoria Delgado⁹, Brian A Ference¹⁰, Ian M Graham¹¹, Alison Halliday¹², Ulf Landmesser¹³, Borislava Mihaylova¹⁴, Terje R Pedersen¹⁵, Gabriele Riccardi¹⁶, Dimitrios J Richter¹⁷, Marc S Sabatine¹⁸, Marja-Riitta Taskinen¹⁹, Lale Tokgozoglu²⁰, Olov Wiklund²¹, Stephan Windecker²², Victor Aboyans²³, Colin Baigent²⁴, Jean-Philippe Collet²³, Veronica Dean²³, Victoria Delgado²⁵, Donna Fitzsimons²⁴, Chris P Gale²⁴, Diederick Grobbee²⁵, Sigrun Halvorsen²⁶, Gerhard Hindricks²⁷, Bernard Iung²³, Peter Jüni²⁸, Hugo A Katus²⁷, Ulf Landmesser²⁷, Christophe Leclercq²³, Maddalena Lettino²⁹, Basil S Lewis³⁰, Bela Merkely³¹, Christian Mueller²², Steffen Petersen²⁴, Anna Sonia Petronio²⁹, Dimitrios J Richter³², Marco Roffi²², Evgeny Shlyakhto³³, Iain A Simpson²⁴, Miguel Sousa-Uva³⁴, Rhian M Touyz²⁴, Djamaleddine Nibouche³⁵, Parounak H Zelveian³⁶, Peter Siostrzonek³⁷, Ruslan Najafov³⁸, Philippe van de Borne³⁹, Belma Pojskic⁴⁰, Arman Postadzhiyan⁴¹, Lambros Kypris⁴², Jindřich Špinar⁴³, Mogens Lytken Larsen⁴⁴, Hesham Salah Eldin⁴⁵, Margus Viigimaa⁴⁶, Timo E Strandberg⁴⁷, Jean Ferrières⁴⁸, Rusudan Agladze⁴⁹, Ulrich Laufs⁵⁰, Loukianos Rallidis⁵¹, László Bajnok⁵², Thorbjörn Gudjónsson⁵³, Vincent Maher⁵⁴, Yaakov Henkin⁵⁵, Michele Massimo Gulizia⁵⁶, Aisulu Mussagaliyeva⁵⁷, Gani Bajraktari⁵⁸, Alina Kerimkulova⁵⁹, Gustavs Latkovskis⁶⁰, Omar Hamoui⁶¹, Rimvydas Slapikas⁶², Laurent Visser⁶³, Philip Dingli⁶⁴, Victoria Ivanov⁶⁵, Aneta Boskovic⁶⁶, Mbarek Nazzi⁶⁷, Frank Visseren⁶⁸, Irena Mitevska⁶⁹, Kjetil Retterstøl⁷⁰, Piotr Jankowski⁷¹, Ricardo Fontes-Carvalho⁷², Dan Gaita⁷³, Marat Ezhov⁷⁴, Marina Foscoli⁷⁵, Vojislav Giga⁷⁶, Daniel Pella⁷⁷, Zlatko Fras⁷⁸, Leopoldo Perez de Isla⁷⁹, Emil Hagström⁸⁰, Roger Lehmann⁸¹, Leila Abid⁸², Oner Ozdogan⁸³, Olena Mitchenko⁸⁴, Riyaz S Patel⁸⁵

Affiliations

¹ Cardiology Department, Geneva University Hospital, 4 Gabrielle-Perret-Gentil, 1211, Geneva, Switzerland. Electronic address: francois.mach@hcuge.ch.
² Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, United Kingdom. Electronic address: colin.baigent@ndph.ox.ac.uk.
³ Department of Pharmacological and Biomolecular Sciences, University of Milan, Multimedica IRCCS, Via Balzaretti, 9, 20133, Milan, Italy. Electronic address: alberico.catapano@unimi.it.
⁴ Cardiology, Bern University Hospital (Inselspital), Bern, Switzerland.
⁵ Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences (DiSFeB), University of Milan, Milan, Italy; IRCCS MultiMedica, Sesto S. Giovanni, Milan, Italy.
⁶ Cardiovascular Program-ICCC and CiberCV, IR-Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
⁷ National Institute for Health and Medical Research (INSERM), Paris, France; Division of Endocrinology- Metabolism, Pitie-Salpetriere University Hospital, Paris, France; Sorbonne University, Paris, France.
⁸ Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
⁹ Cardiology, Leiden University Medical Center, Leiden, Netherlands.
¹⁰ Centre for Naturally Randomized Trials, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
¹¹ Cardiology, Trinity College, Dublin, Ireland.
¹² Nuffield Department of Surgery, University of Oxford, NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
¹³ Department of Cardiology, Charite Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany; German Center of Cardiovascular Research (DZHK), Berlin, Germany.
¹⁴ Nuffield Department of Population Health, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom; Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
¹⁵ Preventive Cardiology, Oslo University Hospital, Aker, Oslo, Norway.
¹⁶ Clinical Medicine and Surgery, Federico II University, Naples, Italy.
¹⁷ Cardiac Department, Euroclinic, Athens, Greece.
¹⁸ TIMI Study Group, Division of Cardiovascular Medicine, Brigham, Women's Hospital and Harvard Medical School, Boston, MA, United States of America.
¹⁹ Research Program for Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland.
²⁰ Cardiology, Hacettepe University, Ankara, Turkey.
²¹ Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
²² Switzerland.
²³ France.
²⁴ United Kingdom.
²⁵ Netherlands.
²⁶ Norway.
²⁷ Germany.
²⁸ Canada.
²⁹ Italy.
³⁰ Israel.
³¹ Hungary.
³² Greece.
³³ Russian Federation.
³⁴ Portugal.
³⁵ Algerian Society of Cardiology, Algeria.
³⁶ Armenian Cardiologists Association, Armenia.
³⁷ Austrian Society of Cardiology, Austria.
³⁸ Azerbaijan Society of Cardiology, Azerbaijan.
³⁹ Belgian Society of Cardiology, Belgium.
⁴⁰ Association of Cardiologists of Bosnia and Herzegovina, Bosnia and Herzegovina.
⁴¹ Bulgarian Society of Cardiology, Bulgaria.
⁴² Cyprus Society of Cardiology, Cyprus.
⁴³ Czech Society of Cardiology, Czech Republic.
⁴⁴ Danish Society of Cardiology, Denmark.
⁴⁵ Egyptian Society of Cardiology, Egypt.
⁴⁶ Estonian Society of Cardiology, Estonia.
⁴⁷ Finnish Cardiac Society, Finland.
⁴⁸ French Society of Cardiology, France.
⁴⁹ Georgian Society of Cardiology, Georgia.
⁵⁰ German Cardiac Society, Germany.
⁵¹ Hellenic Society of Cardiology, Greece.
⁵² Hungarian Society of Cardiology, Hungary.
⁵³ Icelandic Society of Cardiology, Iceland.
⁵⁴ Irish Cardiac Society, Ireland.
⁵⁵ Israel Heart Society, Israel.
⁵⁶ Italian Federation of Cardiology, Italy.
⁵⁷ Association of Cardiologists of Kazakhstan, Kazakhstan.
⁵⁸ Kosovo Society of Cardiology, Republic of Kosovo.
⁵⁹ Kyrgyz Society of Cardiology, Kyrgyzstan.
⁶⁰ Latvian Society of Cardiology, Latvia.
⁶¹ Lebanese Society of Cardiology, Lebanon.
⁶² Lithuanian Society of Cardiology, Lithuania.
⁶³ Luxembourg Society of Cardiology, Luxembourg.
⁶⁴ Maltese Cardiac Society, Malta.
⁶⁵ Moldavian Society of Cardiology, Republic of Moldova.
⁶⁶ Montenegro Society of Cardiology, Montenegro.
⁶⁷ Moroccan Society of Cardiology, Morocco.
⁶⁸ Netherlands Society of Cardiology, Netherlands.
⁶⁹ North Macedonian Society of Cardiology, North Macedonia.
⁷⁰ Norwegian Society of Cardiology, Norway.
⁷¹ Polish Cardiac Society, Poland.
⁷² Portuguese Society of Cardiology, Portugal.
⁷³ Romanian Society of Cardiology, Romania.
⁷⁴ Russian Society of Cardiology, Russian Federation.
⁷⁵ San Marino Society of Cardiology, San Marino.
⁷⁶ Cardiology Society of Serbia, Serbia.
⁷⁷ Slovak Society of Cardiology, Slovakia.
⁷⁸ Slovenian Society of Cardiology, Slovenia.
⁷⁹ Spanish Society of Cardiology, Spain.
⁸⁰ Swedish Society of Cardiology, Sweden.
⁸¹ Swiss Society of Cardiology, Switzerland.
⁸² Tunisian Society of Cardiology and Cardio-Vascular Surgery, Tunisia.
⁸³ Turkish Society of Cardiology, Turkey.
⁸⁴ Ukrainian Association of Cardiology, Ukraine.
⁸⁵ British Cardiovascular Society, United Kingdom of Great Britain and Northern Ireland.

PMID: 31591002
DOI: 10.1016/j.atherosclerosis.2019.08.014

No abstract available

Keywords: Apolipoprotein B; Cholesterol;; Dyslipidaemias; Familial hypercholesterolaemia; Guidelines; High-density lipoproteins; Lipoprotein remnants; Lipoprotein(a); Low-density lipoproteins; Total cardiovascular risk; Treatment (adherence); Treatment (drugs); Treatment (lifestyle); Triglycerides; Very low-density lipoproteins.

Publication types

Practice Guideline
Review

MeSH terms

Adult
Aged
Biomarkers / blood
Cardiovascular Diseases / diagnosis
Cardiovascular Diseases / epidemiology
Cardiovascular Diseases / prevention & control*
Consensus
Drug Therapy, Combination
Dyslipidemias / blood
Dyslipidemias / diagnosis
Dyslipidemias / drug therapy*
Dyslipidemias / epidemiology
Female
Humans
Hypolipidemic Agents / adverse effects
Hypolipidemic Agents / therapeutic use*
Lipids / blood*
Male
Middle Aged
Risk Assessment
Risk Factors
Risk Reduction Behavior
Treatment Outcome

Substances

Biomarkers
Hypolipidemic Agents
Lipids